PerkinElmer ( has become the exclusive provider of Axxam’s ( Photina® photoprotein technology to the drug discovery market. The luminescent cell-based assay platform is optimized for screening drug discovery targets, including G-protein coupled receptors (GPCRs) and ion channels.

The terms of the worldwide licensing agreement also provide for a formal research and development program between PerkinElmer and Axxam to develop additional Photina GPCR and ion channel cell lines for use in high-throughput screening and compound profiling. Axxam retains the rights to use the technology for its discovery services to third parties.

Next articleUMMZ Periodical Cicada Page